TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12776028

Group type: EXPERIMENTAL
Intervention: Z-stent
Number of subjects: 145

Group type: COMPARATOR
Intervention: Wallstent
Number of subjects: 145
Study: 11032201

Group type: EXPERIMENTAL
Intervention: Enhanced back care plus manual therapy
Number of subjects: 191

Group type: COMPARATOR
Intervention: Enhanced back care
Number of subjects: 191
Study: 10072995

Group type: EXPERIMENTAL
Intervention: 99mTc-MIBI SPECT imaging
Number of subjects: 74
Study: 8330997

Group type: EXPERIMENTAL
Intervention: 1.6 Gy twice daily, 5 days a week, with total brain treatment to 32.0 Gy and boost doses escalating from 16.0 Gy to 42.40 Gy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled primary tumors, non-lung primaries, and solitary metastasis.
Number of subjects: 0
Study: 3299287

Group type: EXPERIMENTAL
Intervention: Porcine insulin (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Human insulin (group C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Good metabolic control (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Good metabolic control (group D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (group K)
Number of subjects: 30
Study: 29265791

Group type: EXPERIMENTAL
Intervention: VR-augmented RAGT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard RAGT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 20
Study: 27481306

Group type: EXPERIMENTAL
Intervention: Outreach plus $5 incentive
Number of subjects: 8656

Group type: EXPERIMENTAL
Intervention: Outreach plus $10 incentive
Number of subjects: 8656

Group type: COMPARATOR
Intervention: Outreach (no incentive)
Number of subjects: 8656

Group type: EXPERIMENTAL
Intervention: Outreach plus any financial incentive
Number of subjects: 8656
Study: 24909254

Group type: EXPERIMENTAL
Intervention: Behavioral mother training (BMT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Verbal self-instruction to the children (VSI)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 22230826

Group type: EXPERIMENTAL
Intervention: Integrated care intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 20397458

Group type: EXPERIMENTAL
Intervention: Warm-needling plus Tuina relaxing
Number of subjects: 98

Group type: COMPARATOR
Intervention: Hormone block therapy and drug medication
Number of subjects: 98
Study: 18680246

Group type: EXPERIMENTAL
Intervention: 10 mg dexrabeprazole daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 mg rabeprazole daily
Number of subjects: 0
Study: 16185308

Group type: EXPERIMENTAL
Intervention: Oxytocin treatment (nasal inhalation, twice daily for 13 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo treatment (nasal inhalation, twice daily for 13 weeks)
Number of subjects: 59
Study: 14986908

Group type: EXPERIMENTAL
Intervention: Oral health education program and supervised tooth brushing with fluoridated toothpaste (1100 ppm F‐) in test group (n = 258)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Control group (n = 256) with no oral health education and no supervised tooth brushing
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Parents of children in the test group
Number of subjects: 514
Study: 10634838

Group type: EXPERIMENTAL
Intervention: Trophic feeding (0.5‐1 ml/h) along with parenteral nutrition
Number of subjects: 100

Group type: COMPARATOR
Intervention: Parenteral nutrition alone
Number of subjects: 100
Study: 8803511

Group type: EXPERIMENTAL
Intervention: Continuous running at 95 and 105% of vMTT
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intermittent running at 95 and 105% of vMTT
Number of subjects: 7
Study: 1466894

Group type: EXPERIMENTAL
Intervention: Intracavitary application of 226Ra plus external radiotherapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: 252Cf, 226Ra and extended radiotherapy
Number of subjects: 2
Study: 6489151

Group type: EXPERIMENTAL
Intervention: High methadone dose increase to 60 mg in week 4, then gradual reduction to 30 mg by week 10.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Constant 30 mg methadone dose through treatment week 10.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High methadone dose increase group (experimental)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Constant 30 mg methadone dose group (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 30157839

Group type: EXPERIMENTAL
Intervention: Pretreatment educational programme followed by treatment as usual
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 93
Study: 27155741

Group type: EXPERIMENTAL
Intervention: Pictilisib (340 mg in part 1; 260 mg in part 2) plus fulvestrant 500 mg
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant 500 mg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Pictilisib (340 mg in part 1; 260 mg in part 2)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 24581309

Group type: EXPERIMENTAL
Intervention: Qualitative exploration of psychological distress management strategies among mothers
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Screening for psychological distress using the GHQ-12
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Interventions to address gender inequity and improve access to perinatal healthcare
Number of subjects: 22
Study: 22416676

Group type: EXPERIMENTAL
Intervention: Treatment Interruption (TI) arm
Number of subjects: 54

Group type: COMPARATOR
Intervention: Treatment Continuation (TC) arm
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 54
Study: 20399687

Group type: EXPERIMENTAL
Intervention: 3.0 T MRA
Number of subjects: 19

Group type: COMPARATOR
Intervention: 1.5 T MRA
Number of subjects: 19
Study: 18826999

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 1766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1766
Study: 15955382

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/day)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 91
Study: 12216432

Group type: EXPERIMENTAL
Intervention: Oral continuous 17-beta estradiol and norethindrone acetate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Transdermal cyclic 17-beta estradiol and norethindrone acetate
Number of subjects: 50
Study: 10215734

Group type: EXPERIMENTAL
Intervention: LCM (lansoprazole, clarithromycin, metronidazole)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: LAC (lansoprazole, amoxycillin, clarithromycin)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: CALM (lansoprazole, clarithromycin, amoxycillin)
Number of subjects: 168
Study: 7887385

Group type: EXPERIMENTAL
Intervention: Fosinopril 10 or 20 mg/day
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 241
Study: 2532927

Group type: EXPERIMENTAL
Intervention: Terbinafine (SF 86-327, Lamisil) 250 mg daily for 6 months (finger-nail) and 12 months (toe-nail)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Terbinafine (SF 86-327, Lamisil) 250 mg daily
Number of subjects: 30
Study: 57520

Group type: EXPERIMENTAL
Intervention: WRL 105 strain live influenza vaccine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Alice strain live influenza vaccine
Number of subjects: 45
Study: 29982714

Group type: EXPERIMENTAL
Intervention: First-year eGFR variability measured by coefficient of variation (eGFR-CV)
Number of subjects: 5092

Group type: EXPERIMENTAL
Intervention: First-year eGFR variability measured by percent change (eGFR-PC)
Number of subjects: 5092

Group type: EXPERIMENTAL
Intervention: First-year eGFR variability measured by absolute difference (eGFR-AD)
Number of subjects: 5092

Group type: EXPERIMENTAL
Intervention: First-year eGFR variability measured by slope (eGFR-slope)
Number of subjects: 5092

Group type: EXPERIMENTAL
Intervention: First-year eGFR variability measured by area under the curve (eGFR-AUC)
Number of subjects: 5092

Group type: EXPERIMENTAL
Intervention: High quartile of eGFR-CV with declining quartiles of other eGFR change scales
Number of subjects: 5092
Study: 28931617

Group type: EXPERIMENTAL
Intervention: Normobaric hyperoxia (NBO) treatment (100% O2) in rats during middle cerebral artery occlusion.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normobaric hyperoxia (NBO) treatment in patients with AIS receiving intravenous tPA thrombolysis.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normoxia, 21% O2) in rats during middle cerebral artery occlusion.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (room air) in patients with AIS.
Number of subjects: 0
Study: 26241428

Group type: EXPERIMENTAL
Intervention: Prenatal supervised pelvic floor muscle training
Number of subjects: 282

Group type: COMPARATOR
Intervention: Written instructions on pelvic floor exercises (Control)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Both groups received written instructions about how to perform exercises at home
Number of subjects: 282
Study: 23494931

Group type: EXPERIMENTAL
Intervention: Sildenafil plus testosterone gel (n=70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sildenafil plus placebo gel (n=70)
Number of subjects: 140
Study: 21081772

Group type: EXPERIMENTAL
Intervention: Acupoint stimulation group (ASG; bilateral transcutaneous electrical acupoint stimulation at Neiguan, PC‐6)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional promotility drug treatment group (DTG; metoclopramide, cisapride, erythromycin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acupoint stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional promotility drugs
Number of subjects: 30
Study: 19689171

Group type: EXPERIMENTAL
Intervention: Point-of-care testing (PoCT) in intervention practices using devices such as Siemens DCA 2000 for HbA1c and urine ACR, Cholestech LDX for lipids, and Roche CoaguChek S for INR.
Number of subjects: 4968

Group type: EXPERIMENTAL
Intervention: Initial training workshops for device operators.
Number of subjects: 4968

Group type: EXPERIMENTAL
Intervention: Refresher training workshops for device operators.
Number of subjects: 4968

Group type: EXPERIMENTAL
Intervention: Post-Trial satisfaction questionnaire for device operators.
Number of subjects: 4968

Group type: EXPERIMENTAL
Intervention: Satisfaction survey completed by device operators after initial training workshops.
Number of subjects: 4968

Group type: EXPERIMENTAL
Intervention: Overall PoCT training resources and workshop evaluation.
Number of subjects: 4968
Study: 16949830

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted reperfusion (LD group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Whole blood reperfusion (Control group)
Number of subjects: 40
Study: 10818079

Group type: EXPERIMENTAL
Intervention: Fasidotril (100 mg twice daily for 6 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 8895272

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Droperidol 0.625 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 48
Study: 2066846

Group type: EXPERIMENTAL
Intervention: Methadone (0.2 mg/kg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Morphine (0.2 mg/kg)
Number of subjects: 35
Study: 6133103

Group type: EXPERIMENTAL
Intervention: Advice on cholesterol-lowering diet, smoking cessation, weight control, exercise, and treatment of hypertension.
Number of subjects: 18210
Study: 30625070

Group type: EXPERIMENTAL
Intervention: Caplacizumab (10 mg intravenous loading bolus, followed by 10 mg daily subcutaneously)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 145
Study: 29077240

Group type: COMPARATOR
Intervention: Live Tissue (LT)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Synthetic Training Models (STM)
Number of subjects: 559
Study: 26731754

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 24215845

Group type: EXPERIMENTAL
Intervention: Brostallicin 10mg/m²
Number of subjects: 118

Group type: COMPARATOR
Intervention: Doxorubicin 75mg/m²
Number of subjects: 118
Study: 22439822

Group type: EXPERIMENTAL
Intervention: Onion powder (OP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Apple peel powder (AP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mixture of apple peel and onion powder enriched applesauce (MP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison of OP to AP
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gender-related differences
Number of subjects: 16
Study: 20421444

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus Lcr35
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Escherichia coli Nissle
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 17920475

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated stem
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard blasted stem
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both stems
Number of subjects: 20
Study: 15682366

Group type: EXPERIMENTAL
Intervention: Gated SPECT cardiac quantification (GSCQ) method
Number of subjects: 0
Study: 12131314

Group type: EXPERIMENTAL
Intervention: 3.9 mg daily oxybutynin TDS
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 2.6 mg daily oxybutynin TDS
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study: 10102962

Group type: EXPERIMENTAL
Intervention: Triple therapy (1 g sucralfate q.d.s. for 28 days, 300 mg metronidazole q.d.s. for 14 days, 250 mg clarithromycin q.d.s. for 14 days)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Omeprazole (20 mg q.d.s. for 12 months)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Omeprazole group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Triple therapy group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: H. pylori negative patients
Number of subjects: 114

Group type: COMPARATOR
Intervention: H. pylori positive patients
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: H. pylori negative patients after mean follow-up of 4.07 years
Number of subjects: 114

Group type: COMPARATOR
Intervention: H. pylori positive patients after mean follow-up of 4.07 years
Number of subjects: 114
Study: 8528688

Group type: EXPERIMENTAL
Intervention: Enhanced services group (mandatory school and work requirements, financial sanctions, support services such as case management, parenting workshops, child care assistance, education and training opportunities)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular services group (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced services group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced services group (most engaged in self-sufficiency activities)
Number of subjects: 0
Study: 2262904

Group type: EXPERIMENTAL
Intervention: Zolpidem (15, 30 and 45 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25, 0.5 and 0.75 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30324837

Group type: EXPERIMENTAL
Intervention: 1 mg/day estradiol valerate plus 4 mg/day medroxyprogesterone acetate on days 19‐30 (Group A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1 mg/day estradiol valerate plus 100 mg/day micronized progesterone on days 19‐30 (Group B)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cimicifuga foetida extract, 1 tablet (contains 33.3 mg extract), t.i.d. (Group C)
Number of subjects: 96
Study: 30022759

Group type: EXPERIMENTAL
Intervention: Pidotimod oral liquid
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional treatment (ganciclovir for injection and symptomatic treatment)
Number of subjects: 76
Study: 27030629

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposure (IHE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment (C)
Number of subjects: 16
Study: 25377429

Group type: EXPERIMENTAL
Intervention: Pregabalin 2.5 mg/kg/day
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pregabalin 5 mg/kg/day
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pregabalin 10 mg/kg/day
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pregabalin 15 mg/kg/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pregabalin (all doses)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pregabalin (up to 10 mg/kg/day for ages 1 month to 16 years; up to 15 mg/kg/day for ages <6 years)
Number of subjects: 65
Study: 22202713

Group type: EXPERIMENTAL
Intervention: Transpulmonary thermodilution
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pulmonary artery catheter
Number of subjects: 120
Study: 21512813

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg intravenously before tourniquet inflation and 3 hours postoperatively; 250 mg orally, two capsules three times daily for 5 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 100
Study: 17284888

Group type: EXPERIMENTAL
Intervention: 5‐h sleep restriction (from 0100 to 0600) for 7 d
Number of subjects: 13

Group type: COMPARATOR
Intervention: 8‐h sleep (from 2300 to 0700) for 7 d
Number of subjects: 13
Study: 16060124

Group type: EXPERIMENTAL
Intervention: Torsemide (29 mg, range 0-160 mg) every 6 h
Number of subjects: 29

Group type: COMPARATOR
Intervention: Furosemide (60 mg, range 0-240 mg) every 6 h
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Torsemide and Furosemide (both groups)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Furosemide group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Torsemide group
Number of subjects: 29
Study: 12017410

Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/d
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 10399974

Group type: EXPERIMENTAL
Intervention: Xylocaine (short-acting anesthetic)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Bupivacaine (long-acting anesthetic)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 99
Study: 7752872

Group type: EXPERIMENTAL
Intervention: Strength-only (S) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Endurance-only (E) group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined (C) group
Number of subjects: 30
Study: 2277569

Group type: EXPERIMENTAL
Intervention: Low dose epidural morphine (2 mg) and 75 mg diclofenac sodium i.m. postoperatively (Group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low dose epidural morphine (2 mg) and 3 ml normal saline i.m. at recovery room (Group A)
Number of subjects: 50
Study: 316976

Group type: EXPERIMENTAL
Intervention: Prophylactic propranolol treatment postoperatively
Number of subjects: 42

Group type: COMPARATOR
Intervention: No prophylaxis (nontreatment group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1 mg of intravenous propranolol therapy
Number of subjects: 42
Study: 31587479

Group type: EXPERIMENTAL
Intervention: Molecular and histopathological study using PCR assays and histopathology on ocular tissues
Number of subjects: 100
Study: 31160473

Group type: EXPERIMENTAL
Intervention: Standardized Patient (SP) method
Number of subjects: 87

Group type: COMPARATOR
Intervention: Lecture-based education method (Control)
Number of subjects: 87
Study: 29016626

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Standard dose of PPI
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High dose of PPI
Number of subjects: 27
Study: 26693446

Group type: EXPERIMENTAL
Intervention: Obtuse curved shaft needles
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Arch-shape shaft needles
Number of subjects: 45

Group type: COMPARATOR
Intervention: Straight shaft needles
Number of subjects: 45
Study: 22866876

Group type: EXPERIMENTAL
Intervention: Project ROADMAP intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 22023278

Group type: EXPERIMENTAL
Intervention: Positive interpretation bias modification
Number of subjects: 67

Group type: COMPARATOR
Intervention: Negative interpretation bias modification
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Bias modification (both positive and negative)
Number of subjects: 67
Study: 19810125

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemoradiotherapy (CCRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) and hyperfractionation (HF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 0
Study: 17309587

Group type: EXPERIMENTAL
Intervention: New brush heads
Number of subjects: 34

Group type: COMPARATOR
Intervention: 3-month-old worn brush heads
Number of subjects: 34
Study: 15521106

Group type: EXPERIMENTAL
Intervention: Penicillin (800 mg/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC; 1 mg/kg.day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of penicillin and DEC (at the same doses)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Framycetin ointment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo tablets and placebo ointment
Number of subjects: 150
Study: 11437861

Group type: EXPERIMENTAL
Intervention: Diabetes specialist nursing (DSN) service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard in‐patient care (Control)
Number of subjects: 0
Study: 9684133

Group type: EXPERIMENTAL
Intervention: Multivitamin infusion (Omnibionta) including 10 mg of alpha‐tocopherol acetate, 2 mg of DL‐alpha‐tocopherol, and 1 g of ascorbate
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Multivitamin infusion (Omnibionta)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no antioxidant treatment)
Number of subjects: 58